C8orf76 Promotes Gastric Tumorigenicity and Metastasis by Directly Inducing lncRNA DUSP5P1 and Associates with Patient Outcomes

Purpose: We identified for the first time that C8orf76 (chromosome 8 open reading frame 76) is preferentially amplified in gastric cancer. We elucidated its role and clinical significance in gastric carcinogenesis. Experimental Design: The clinical impact of C8orf76 was assessed in 592 patients with gastric cancer. The biological function of C8orf76 was studied in vitro, in vivo, and in gastric cancer patient-derived organoid models. C8orf76 downstream effector and pathways were identified by RNA sequencing, chromatin immunoprecipitation sequencing, luciferase reporter, and electrophoretic mobility shift assay. Results: C8orf76 was upregulated in 69.74% and 65.71% of two independent cohorts of gastric cancers and was positively associated with C8orf76 amplification. Multivariate analysis showed that gastric cancer patients with C8orf76 amplification (cohort I, n = 129; cohort II, n = 107) or overexpression (n = 356) had a significantly shortened survival. C8orf76 significantly promoted gastric cancer cell proliferation, cell-cycle transformation, and migration/invasion, but suppressed cell apoptosis. Silencing C8orf76 expression exerted opposite effects in vitro and significantly inhibited xenograft tumor growth, lung metastasis, and liver metastasis in nude mice. Silencing C8orf76 also significantly suppressed the growth of patient-derived organoids. Mechanically, C8orf76 activated MAPK/ERK signaling cascade. C8orf76 directly bound to the promoter region of lncRNA dual specificity phosphatase 5 pseudogene 1 (DUSP5P1) with a binding motif of AGGCTG and activated DUSP5P1 transcription. DUSP5P1 induced MAPK/ERK signaling and promoted gastric tumorigenesis. Knockdown DUSP5P1 abrogated the effect of C8orf76 in activating MAPK/ERK cascade and the tumor-promoting function. Conclusions: C8orf76 directly binds to oncogenic lncRNA DUSP5P1 to induce its expression and activates MAPK signaling. C8orf76 plays a pivotal oncogenic role in gastric carcinogenesis and is an independent prognostic factor for gastric cancer patients.

[1]  J. Qian,et al.  High expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) is associated with poor prognosis in acute myeloid leukemia. , 2015, International journal of clinical and experimental pathology.

[2]  Mei-hua Yang,et al.  Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer. , 2015, World journal of gastroenterology.

[3]  Joobae Park,et al.  Copy Number Gains at 8q24 and 20q11-q13 in Gastric Cancer Are More Common in Intestinal-Type than Diffuse-Type , 2015, PloS one.

[4]  Jun Yu,et al.  MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome , 2015, Gut.

[5]  P. Lipp,et al.  Direct Nkx2‐5 Transcriptional Repression of Isl1 Controls Cardiomyocyte Subtype Identity , 2015, Stem cells.

[6]  G. Sauter,et al.  Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer , 2015, BMC Gastroenterology.

[7]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[8]  D. Körholz,et al.  Expression of Dual-Specificity Phosphatase 5 Pseudogene 1 (DUSP5P1) in Tumor Cells , 2014, PloS one.

[9]  M. Hidalgo,et al.  Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Morris,et al.  Not so pseudo anymore: pseudogenes as therapeutic targets. , 2013, Pharmacogenomics.

[11]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[12]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[13]  P. Fortina,et al.  ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. , 2012, The Journal of clinical investigation.

[14]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[15]  G. Pagès,et al.  The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. , 2010, American journal of physiology. Cell physiology.

[16]  R. Pulido,et al.  Differential Up-regulation of MAP Kinase Phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun Converge in the Control of the Growth Arrest Versus Proliferation Response of MCF-7 Breast Cancer Cells to Phorbol Ester* , 2010, The Journal of Biological Chemistry.

[17]  K. Patterson,et al.  Dual-specificity phosphatases: critical regulators with diverse cellular targets. , 2009, The Biochemical journal.

[18]  Qian Tao,et al.  Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. , 2009, Gastroenterology.

[19]  Sunghoon Kim,et al.  The Haploinsufficient Tumor Suppressor p18 Upregulates p53 via Interactions with ATM/ATR , 2005, Cell.

[20]  T. Chiba,et al.  Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway , 2003, Oncogene.

[21]  J. Ji,et al.  Recurrent amplification of MYC and TNFRSF11B in 8q24 is associated with poor survival in patients with gastric cancer , 2015, Gastric Cancer.

[22]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.